Phase 3 N=471 Stimulant Abuser Groups to Engage in 12-Step
Drug Abuse
Primary: Days of Stimulant Use — 2.35; 2.13 days of stimulant use — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=36 Effect of Stimulant Drugs on Social Perception
Healthy · MDMA ('Ecstasy')
Primary: Responses to Affective Touch — -1.24; 0.12; 0.19; 0.25 units on a scale
N/A N=129 rTMS for Stimulant Use Disorders
Cocaine Use Disorder · Methamphetamine Abuse · Cocaine Dependence
Primary: Percentage of Participants Who Receive at Least 20 Sessions of rTMS/Sham Over the Treatment Period. — 29; 40; 37; 23 Participants
Phase 2 N=23 Caffeine and Cocaine
Cocaine Dependence
Primary: Visual Analog Scale Subjective Rating of Drug Effects — 8.65; 9.85; 13.65; 10.43 units on a scale
N/A N=235 Preventing Prescription Stimulant Diversion and Medication Misuse Via a Web-Based Simulation Intervention
Prescription Drug Abuse (Not Dependent) · Intentional Misuse
Primary: Frequency of Prescription Stimulant Diversion — .25; .41; .18; .30 Mean number of times diverted — p=.499
Phase 2 N=40 Stimulant Oxytocin Study
Stimulant Use & Co-occuring Opioid Use Disorders
Primary: Number of Participants With Stimulant Positive Drug Screen — 9; 12; 9; 10 Participants
Phase 4 N=33 Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
Attention Deficit Disorder With Hyperactivity · Conduct Disorder · Substance Abuse
Primary: Change in fMRI Measure — -0.957100; 0.572517; -0.139000; 1.876717 BOLD signal
Phase 2 N=170 Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men
HIV Seroconversion · Stimulant Abuse
Primary: Time From Exposure to Truvada Initiation — 32.8; 33.0 hours
Phase 1 N=8 Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Phase 2 N=20 Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction
Cocaine Addiction · Cocaine-related Disorder · Executive Dysfunction
Primary: Abstinence — 71.4; 16.6 percentage of participants
Phase 2 N=13 Suvorexant for Opioid/Stimulant Co-use
Opioid Use Disorder · Stimulant Use Disorder
Primary: Opioid Use: Proportion of Positive Urine Drug Screens (UDS) — 0.83; 0.67 Proportion of urine drug screens
Early Phase 1 N=18 Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
Active Cocaine Users
Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 0.06; 0.94; 0.75; 0.88 cocaine choices
Phase 1 N=93 Differential Responses to Drugs and Sweet Tastes
Bipolar II Disorder
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 18.88…
Phase 2 N=22 Doxazosin for Psychostimulant Dependence
Methamphetamine or Cocaine Dependence
Primary: Change in Psychostimulant-positive Urines Over Time — .6; .41; .79; .25 proportion of psychostimulant-pos urines — p=0.05
Phase 2 N=35 Studying Amphetamine Withdrawal in Humans
Methamphetamine Dependence
Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale
Phase 4 N=40 Effects of Modafinil in Methamphetamine Dependence
Methamphetamine Dependence
Primary: Percentage of Participants With Methamphetamine-positive Urine Drug Screens — 85; 65 Percentage of participants
Phase 3 N=538 Smoking-Cessation and Stimulant Treatment (S-CAST)
Cocaine Dependence · Methamphetamine Dependence · Nicotine Dependence
Primary: Stimulant-free Weeks Assessed by Self-report and Twice-weekly Urine Drug Screens — 77.7; 78.0 percentage of weeks
Phase 2 N=13 Modafinil for Smoked Cocaine Self-Administration
Cocaine Dependence
Primary: Cocaine Self-administration — 0; 0; 0; 2.2 Number of doses purchased
Phase 2 N=71 Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
Methamphetamine Dependence
Primary: Clean Urine Drug Screen — 13.1; 12.7 Clean urine drug screens
Phase 4 N=14 Creatine as a Treatment Option for Depression in Methamphetamine Using Females
Depression · Substance Abuse · Substance Use
Primary: HAMD Rating Scores — 16.86; 10.71; 9.81; 7.33 Units on a scale
N/A N=8 Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
Methamphetamine Dependence · Methamphetamine Withdrawal
Primary: Methamphetamine Selective Severity Assessment (MSSA) — 48.2 "units on a scale" — p=<0.05
Phase 2 N=20 Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity · Cocaine-Related Disorders
Primary: the Adult ADHD Rating Scale (AARS) (30% Reduction) — 50 percent of participants
Phase 2 N=50 Psychopharmacology for Cocaine Dependence - Buspirone
Cocaine Dependence
Primary: Attentional Bias as Assessed by Score on the Stroop Task — -13.90333; 27.118; -9.361269; 15.35407 milliseconds
N/A N=38 Non-Invasive Brain Stimulation and Substance Use
Substance Use Disorders
Primary: Change in Distress Tolerance (Mean Latency to Quit the PASAT-C) — 11.2; 9.8; 9.4 minutes
Phase 4 N=14 Effect of Methamphetamine on Residual Latent HIV Disease Study
HIV-1-infection · Methamphetamine-dependence
Primary: HIV Transcription (Cell-associated HIV RNA) in Peripheral Blood — 10.45; 57.38 copies/million cells
N/A N=27 Financial Incentives to Promote Stimulant Abstinence in a Community-Based Syringe Exchange Program
Stimulant Use
Primary: Stimulant Free Urine Sample — 6.1; 23.6 % stimulant-negative urine drug test
N/A N=302 Exercise as a Treatment for Substance Use Disorders Protocol
Stimulant Abuse and Dependence
Primary: Percent Days Abstinent — 90.8; 91.6; 75.5; 77.2 Percentage of Days — p=<0.05
Phase 2 N=73 Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals
Cocaine-Related Disorders
Primary: Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment — 9.25; 6.09; 6; 4.91 number of…
Phase 3 N=24 Methylphenidate to Improve Balance and Walking in MS
Multiple Sclerosis
Primary: Change From Baseline in Timed Up and Go (TUG) Test Time at 6 Weeks — -0.7; -1.3 change in seconds from basline
N/A N=24 Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD
Obsessive-Compulsive Disorder
Primary: Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2 — 6; 7 participants